Do You Know

03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *

Products » Items » Lucentis 2.3mg


Contraindicated
Teratogenic, foetotoxic and embryotoxic

Contraindicated
Manque de données
Lucentis 2.3mg :
Type Medicine Authorised
Originator Biotech (Lucentis 2.3mg)
Agent Khalil Fattal & Fils
Distributor Khalil Fattal & Fils
Laboratory Novartis
Responsible Party Novartis Pharma AG
Origin Switzerland
Manufacturer Novartis Pharma Stein AG
Origin Switzerland
ATC S01LA04

Your comment will appear shortly after approval

Lucentis 2.3mg :

Revision Date : 04/07/2013


Effect Frequency
Abnormal sensation in eye Uncommon
Anaemia Common
Anterior chamber flare Common
Anxiety Common
Arthralgia (Pain joint) (Joint ache) Very Common
Blepharitis Very Common
Blindness Uncommon
Cataract Common
Cataract subcapsular Common
Cerebrovascular accident Not known
Conjunctival haemorrhage Very Common
Conjunctival hyperaemia (Conjunctival redness) (Conjunctival injection) Common
Conjunctivitis Common
Conjunctivitis allergic Common
Corneal abrasion Common
Corneal deposits Uncommon
Corneal oedema Uncommon
Corneal striae Uncommon
Cough Common
Detachment of retinal pigment epithelium Common
Dry eye Very Common
Embolism arterial Not known
Endophthalmitis Uncommon
Erythema Common
Eye discharge Common
Eye haemorrhage Common
Eye irritation Very Common
Eye pain Very Common
Eye pruritus Very Common
Eyelid irritation Uncommon
Eyelid oedema Common
Eyelid pain Common
Foreign body sensation in eyes Very Common
Haemorrhage Not known
Headache Very Common
Hypersensitivity Common
Hyphaema Uncommon
Hypopyon Uncommon
Injection site haemorrhage Common
Injection site irritation Uncommon
Injection site pain Uncommon
Intraocular pressure increased Very Common
Iridocyclitis Common
Iris adhesions Uncommon
Iritis Common
Keratopathy Uncommon
Lacrimation increased (Epiphora) Very Common
Myocardial infarction Not known
Nasopharyngitis Very Common
Nausea Common
Ocular discomfort Common
Ocular hyperaemia Very Common
Photophobia Common
Photopsia Common
Posterior capsule opacification Common
Pruritus Common
Punctate keratitis Common
Retinal degeneration Common
Retinal detachment Common
Retinal disorder Common
Retinal haemorrhage Very Common
Retinal pigment epithelial tear Common
Retinal tear Common
Skin rash Common
Urinary tract infection Common
Urticaria Common
Uveitis Common
Vision blurred Common
Visual acuity reduced Common
Visual disturbance Very Common
Vitreous detachment Very Common
Vitreous disorder Common
Vitreous floaters Very Common
Vitreous haemorrhage Common
Vitritis Very Common

Different Units By MoH Code

Revision Date : 01/02/2015

Revision Date : 24/03/2022

Lucentis 2.3mg  MoH 5209 :
Form Solution for injection
Packaging Bottle
Package Size 1x0.23ml
Strength 2.3mg/0.23ml
Storage Condition 2-8°C Do not freeze
Public Price 51541434 L.L.
Stratum E1
NSSF ✔
Quarantine ✔
Reg. Number 24544/07
Submission date 01/01/2007
Registration Year 2007


Price Comparison

● Country: Lebanon
● Form: Solution for injection
● Package Size: 1x0.23ml
● Public Price: 51541434 LBP ( 51,541,434.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 51541434 LBP ( 51,541,434.00 LBP )
● Pricing Date: 10/01/2024

● Country: KSA
● Package Size: 1
● Public Price: 7048.3 SAR ( 28,407,327.35 LBP )
● Pack size unit used: 1
● Cost/Unit: 7048,3 SAR ( 28,406,118.24 LBP )
● Reference: sfda
● Pricing Date: 16/01/2021
● Type: Medicine Authorised

● Country: Qatar
● Package Size: 1x0.23ml
● Public Price: 5456 QAR ( 22,645,455.36 LBP )
● Pack size unit used: 1
● Cost/Unit: 5456 QAR ( 22,645,455.36 LBP )
● Pharmacy Price: 4481.54 QAR ( 18600900.6624 LBP )
● Pricing Date: 28/01/2021
● Type: Medicine Authorised

● Country: Germany
● Package Size: 1x 0.23ml
● Public Price: 1231.18 EUR ( 22,629,149.96 LBP )
● Pack size unit used: 1
● Cost/Unit: 1231,18 EUR ( 22,625,841.55 LBP )
● Pricing Date: 24/10/2020
● Type: Medicine Authorised

● Country: Oman
● Package Size: 1x0.23ml
● Public Price: 574.44 OMR ( 22,575,779.22 LBP )
● Pack size unit used: 1
● Cost/Unit: 574,44 OMR ( 22,558,487.00 LBP )
● Pricing Date: 19/02/2021
● Type: Medicine Authorised

● Country: Abu Dhabi
● Package Size: 1x0.23ml
● Public Price: 5098 AED ( 20,957,674.08 LBP )
● Pack size unit used: 1
● Cost/Unit: 5098 AED ( 20,957,674.08 LBP )
● Pharmacy Price: 4342.89 AED ( 17853447.0744 LBP )
● Pricing Date: 27/01/2021
● Type: Medicine Authorised

● Country: UAE
● Package Size: 1x0.23ml Glass Vial
● Public Price: 5098 AED ( 20,957,674.08 LBP )
● Pack size unit used: 1
● Cost/Unit: 5098 AED ( 20,957,674.08 LBP )
● Pharmacy Price: 4342.89 AED ( 17853447.0744 LBP )
● Pricing Date: 21/08/2019
● Type: Medicine Authorised

● Country: Italy
● Package Size: 1x0.23ml
● Public Price: 1105.2 EUR ( 20,313,631.26 LBP )
● Pack size unit used: 1
● Cost/Unit: 1105,2 EUR ( 20,309,955.25 LBP )
● Exfactory Price: 669.66 EUR
● Pricing Date: 17/12/2019
● Type: Medicine Authorised

● Country: Bahrain
● Package Size: 1x0.23ml
● Public Price: 484.92 BHD ( 19,455,363.79 LBP )
● Pack size unit used: 1
● Cost/Unit: 484,92 BHD ( 19,418,452.68 LBP )
● Reference: nhra
● Pricing Date: 09/02/2021
● Type: Medicine Authorised

● Country: Switzerland
● Package Size: 1x0.23ml
● Public Price: 1020.15 CHF ( 17,404,014.04 LBP )
● Pack size unit used: 1
● Cost/Unit: 1020,15 CHF ( 17,401,455.00 LBP )
● Exfactory Price: 874.34 CHF
● Pricing Date: 04/04/2021
● Type: Medicine Authorised

● Country: Denmark
● Package Size: 1x0,23 ml
● Public Price: 6830 DKK ( 16,808,425.10 LBP )
● Pack size unit used: 1
● Cost/Unit: 6830 DKK ( 16,808,425.10 LBP )
● Pharmacy Price: 5073 DKK ( 12484500.81 LBP )
● Reference: Danish Medicine Agency
● Pricing Date: 19/05/2021
● Type: Medicine Authorised

● Country: The Netherlands
● Package Size: 1x0.23ml
● Public Price: 833.9 EUR ( 15,327,123.70 LBP )
● Pack size unit used: 1
● Cost/Unit: 833,9 EUR ( 15,310,581.65 LBP )
● Pharmacy Price: 826.9 EUR ( 15198463.345 LBP )
● Reference: Zorginstituut Nederland
● Pricing Date: 15/06/2019
● Type: Medicine Authorised

● Country: Spain
● Package Size: 1x0.23ml
● Public Price: 829.83 EUR ( 15,252,316.89 LBP )
● Pack size unit used: 1
● Cost/Unit: 829,83 EUR ( 15,237,061.45 LBP )
● Reference: Agencia Española de Medicamentos y Productos Sanitarios
● Pricing Date: 06/05/2021
● Type: Medicine Authorised

● Country: Cyprus
● Package Size: 1X 023ml
● Public Price: 821.18 EUR ( 15,093,329.46 LBP )
● Pack size unit used: 1
● Cost/Unit: 821,18 EUR ( 15,090,021.05 LBP )
● Reference: Cyprus Minister of Health
● Pricing Date: 24/03/2021
● Type: Medicine Authorised

● Country: Jordan
● Package Size: 1
● Public Price: 687.15 JOD ( 14,663,911.56 LBP )
● Pack size unit used: 1
● Cost/Unit: 687,15 JOD ( 14,660,710.53 LBP )
● Pharmacy Price: 660.72 JOD ( 14099890.3368 LBP )
● Reference: JFDA
● Pricing Date: 02/01/2021
● Type: Medicine Authorised

● Country: Czech Republic
● Package Size: 1x0.23ml
● Public Price: 19394.09 CZK ( 13,396,661.61 LBP )
● Pack size unit used: 1
● Cost/Unit: 19394,09 CZK ( 13,396,599.44 LBP )
● Reference: SUKL
● Pricing Date: 28/02/2020
● Type: Medicine Authorised

● Country: Norway
● Package Size: 1x0.23ml
● Public Price: 7726.2 NOK ( 13,368,412.07 LBP )
● Pack size unit used: 1
● Cost/Unit: 7726,2 NOK ( 13,368,066.02 LBP )
● Pharmacy Price: 6001.93 NOK ( 10384959.4211 LBP )
● Reference: Norwegian Medicine Agency
● Pricing Date: 01/04/2020
● Type: Medicine Authorised

● Country: Belgium
● Package Size: 1x0.23ml
● Public Price: 686 EUR ( 12,608,714.30 LBP )
● Pack size unit used: 1
● Cost/Unit: 686 EUR ( 12,608,714.30 LBP )
● Reference: cbip
● Pricing Date: 18/07/2017
● Type: Medicine Non Marketed

● Country: Greece
● Package Size: 1x0.23ml
● Public Price: 681.02 EUR ( 12,517,181.65 LBP )
● Pack size unit used: 1
● Cost/Unit: 681,02 EUR ( 12,516,814.05 LBP )
● Exfactory Price: 586.09 EUR
● Pharmacy Price: 594.88 EUR ( 10933924.144 LBP )
● Reference: National Organization for Medicines
● Pricing Date: 20/08/2020
● Type: Medicine Authorised

● Country: Sweden
● Package Size: 1x0.23ml
● Public Price: 6489.79 SEK ( 11,682,335.88 LBP )
● Pack size unit used: 1
● Cost/Unit: 6489,79 SEK ( 11,680,913.79 LBP )
● Pharmacy Price: 6317.2 SEK ( 11371654.892 LBP )
● Pricing Date: 27/12/2019
● Type: Medicine Non Marketed

● Country: France
● Package Size: 1x0.23ml
● Public Price: 607.41 EUR ( 11,164,226.17 LBP )
● Pack size unit used: 1
● Cost/Unit: 607,41 EUR ( 11,156,690.35 LBP )
● Reference: ansm
● Pricing Date: 15/05/2021
● Type: Medicine Non Marketed

● Country: UK
● Package Size: 1x0.23ml
● Public Price: 551 GBP ( 11,103,074.27 LBP )
● Pack size unit used: 1
● Cost/Unit: 551 GBP ( 11,103,074.27 LBP )
● Reference: DMD
● Pricing Date: 08/03/2021
● Type: Medicine Authorised

● Country: Egypt
● Package Size: 1x0.23ml
● Public Price: 5600 EGP ( 5,376,560.00 LBP )
● Pack size unit used: 1
● Cost/Unit: 5600 EGP ( 5,376,560.00 LBP )
● Pricing Date: 20/11/2019
● Type: Medicine Authorised

● Country: Turkey
● Package Size: 1
● Public Price: 2618.34 TRY ( 5,029,019.45 LBP )
● Pack size unit used: 1
● Cost/Unit: 2618,34 TRY ( 5,028,366.42 LBP )
● Pricing Date: 28/10/2020
● Type: Medicine Authorised

● Country: Finland
● Package Size: 1x0.23ml
● Reference: Kela
● Pricing Date: 22/04/2021
● Type: Medicine Non Marketed

● Country: Portugal
● Package Size: 1x0.165ml
● Reference: Autoridade Nacional do Medicamento e Produtos de Saúde
● Pricing Date: 22/04/2019

    ◼ Lebanon
    ◼ Country of Origin
    ◼ Reference Countries
    ◼ Other Countries

Note

Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 51541434 LBP ( 51,541,434.00 LBP )
● Cost/Day: 51541434 LBP ( 51,541,434.00 LBP )
● Cost/Month: 51541434 LBP ( 51,541,434.00 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 51541434 LBP ( 51,541,434.00 LBP )
● Cost/Day: 51541434 LBP ( 51,541,434.00 LBP )
● Cost/Month: 51541434 LBP ( 51,541,434.00 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 51541434 LBP ( 51,541,434.00 LBP )
● Cost/Day: 51541434 LBP ( 51,541,434.00 LBP )
● Cost/Month: 51541434 LBP ( 51,541,434.00 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 51541434 LBP ( 51,541,434.00 LBP )
● Cost/Day: 51541434 LBP ( 51,541,434.00 LBP )
● Cost/Month: 51541434 LBP ( 51,541,434.00 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 7048,3 SAR ( 28,406,118.24 LBP )
● Cost/Day: 7048,3 SAR ( 28,406,118.24 LBP )
● Cost/Month: 7048,3 SAR ( 28,406,118.24 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 7048,3 SAR ( 28,406,118.24 LBP )
● Cost/Day: 7048,3 SAR ( 28,406,118.24 LBP )
● Cost/Month: 7048,3 SAR ( 28,406,118.24 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 7048,3 SAR ( 28,406,118.24 LBP )
● Cost/Day: 7048,3 SAR ( 28,406,118.24 LBP )
● Cost/Month: 7048,3 SAR ( 28,406,118.24 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 7048,3 SAR ( 28,406,118.24 LBP )
● Cost/Day: 7048,3 SAR ( 28,406,118.24 LBP )
● Cost/Month: 7048,3 SAR ( 28,406,118.24 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 5456 QAR ( 22,645,455.36 LBP )
● Cost/Day: 5456 QAR ( 22,645,455.36 LBP )
● Cost/Month: 5456 QAR ( 22,645,455.36 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 5456 QAR ( 22,645,455.36 LBP )
● Cost/Day: 5456 QAR ( 22,645,455.36 LBP )
● Cost/Month: 5456 QAR ( 22,645,455.36 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 5456 QAR ( 22,645,455.36 LBP )
● Cost/Day: 5456 QAR ( 22,645,455.36 LBP )
● Cost/Month: 5456 QAR ( 22,645,455.36 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 5456 QAR ( 22,645,455.36 LBP )
● Cost/Day: 5456 QAR ( 22,645,455.36 LBP )
● Cost/Month: 5456 QAR ( 22,645,455.36 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 1231,18 EUR ( 22,625,841.55 LBP )
● Cost/Day: 1231,18 EUR ( 22,625,841.55 LBP )
● Cost/Month: 1231,18 EUR ( 22,625,841.55 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 1231,18 EUR ( 22,625,841.55 LBP )
● Cost/Day: 1231,18 EUR ( 22,625,841.55 LBP )
● Cost/Month: 1231,18 EUR ( 22,625,841.55 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 1231,18 EUR ( 22,625,841.55 LBP )
● Cost/Day: 1231,18 EUR ( 22,625,841.55 LBP )
● Cost/Month: 1231,18 EUR ( 22,625,841.55 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 1231,18 EUR ( 22,625,841.55 LBP )
● Cost/Day: 1231,18 EUR ( 22,625,841.55 LBP )
● Cost/Month: 1231,18 EUR ( 22,625,841.55 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 574,44 OMR ( 22,558,487.00 LBP )
● Cost/Day: 574,44 OMR ( 22,558,487.00 LBP )
● Cost/Month: 574,44 OMR ( 22,558,487.00 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 574,44 OMR ( 22,558,487.00 LBP )
● Cost/Day: 574,44 OMR ( 22,558,487.00 LBP )
● Cost/Month: 574,44 OMR ( 22,558,487.00 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 574,44 OMR ( 22,558,487.00 LBP )
● Cost/Day: 574,44 OMR ( 22,558,487.00 LBP )
● Cost/Month: 574,44 OMR ( 22,558,487.00 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 574,44 OMR ( 22,558,487.00 LBP )
● Cost/Day: 574,44 OMR ( 22,558,487.00 LBP )
● Cost/Month: 574,44 OMR ( 22,558,487.00 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 5098 AED ( 20,957,674.08 LBP )
● Cost/Day: 5098 AED ( 20,957,674.08 LBP )
● Cost/Month: 5098 AED ( 20,957,674.08 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 5098 AED ( 20,957,674.08 LBP )
● Cost/Day: 5098 AED ( 20,957,674.08 LBP )
● Cost/Month: 5098 AED ( 20,957,674.08 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 5098 AED ( 20,957,674.08 LBP )
● Cost/Day: 5098 AED ( 20,957,674.08 LBP )
● Cost/Month: 5098 AED ( 20,957,674.08 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 5098 AED ( 20,957,674.08 LBP )
● Cost/Day: 5098 AED ( 20,957,674.08 LBP )
● Cost/Month: 5098 AED ( 20,957,674.08 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 5098 AED ( 20,957,674.08 LBP )
● Cost/Day: 5098 AED ( 20,957,674.08 LBP )
● Cost/Month: 5098 AED ( 20,957,674.08 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 5098 AED ( 20,957,674.08 LBP )
● Cost/Day: 5098 AED ( 20,957,674.08 LBP )
● Cost/Month: 5098 AED ( 20,957,674.08 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 5098 AED ( 20,957,674.08 LBP )
● Cost/Day: 5098 AED ( 20,957,674.08 LBP )
● Cost/Month: 5098 AED ( 20,957,674.08 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 5098 AED ( 20,957,674.08 LBP )
● Cost/Day: 5098 AED ( 20,957,674.08 LBP )
● Cost/Month: 5098 AED ( 20,957,674.08 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 1105,2 EUR ( 20,309,955.25 LBP )
● Cost/Day: 1105,2 EUR ( 20,309,955.25 LBP )
● Cost/Month: 1105,2 EUR ( 20,309,955.25 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 1105,2 EUR ( 20,309,955.25 LBP )
● Cost/Day: 1105,2 EUR ( 20,309,955.25 LBP )
● Cost/Month: 1105,2 EUR ( 20,309,955.25 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 1105,2 EUR ( 20,309,955.25 LBP )
● Cost/Day: 1105,2 EUR ( 20,309,955.25 LBP )
● Cost/Month: 1105,2 EUR ( 20,309,955.25 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 1105,2 EUR ( 20,309,955.25 LBP )
● Cost/Day: 1105,2 EUR ( 20,309,955.25 LBP )
● Cost/Month: 1105,2 EUR ( 20,309,955.25 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 484,92 BHD ( 19,418,452.68 LBP )
● Cost/Day: 484,92 BHD ( 19,418,452.68 LBP )
● Cost/Month: 484,92 BHD ( 19,418,452.68 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 484,92 BHD ( 19,418,452.68 LBP )
● Cost/Day: 484,92 BHD ( 19,418,452.68 LBP )
● Cost/Month: 484,92 BHD ( 19,418,452.68 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 484,92 BHD ( 19,418,452.68 LBP )
● Cost/Day: 484,92 BHD ( 19,418,452.68 LBP )
● Cost/Month: 484,92 BHD ( 19,418,452.68 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 484,92 BHD ( 19,418,452.68 LBP )
● Cost/Day: 484,92 BHD ( 19,418,452.68 LBP )
● Cost/Month: 484,92 BHD ( 19,418,452.68 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 1020,15 CHF ( 17,401,455.00 LBP )
● Cost/Day: 1020,15 CHF ( 17,401,455.00 LBP )
● Cost/Month: 1020,15 CHF ( 17,401,455.00 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 1020,15 CHF ( 17,401,455.00 LBP )
● Cost/Day: 1020,15 CHF ( 17,401,455.00 LBP )
● Cost/Month: 1020,15 CHF ( 17,401,455.00 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 1020,15 CHF ( 17,401,455.00 LBP )
● Cost/Day: 1020,15 CHF ( 17,401,455.00 LBP )
● Cost/Month: 1020,15 CHF ( 17,401,455.00 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 1020,15 CHF ( 17,401,455.00 LBP )
● Cost/Day: 1020,15 CHF ( 17,401,455.00 LBP )
● Cost/Month: 1020,15 CHF ( 17,401,455.00 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 6830 DKK ( 16,808,425.10 LBP )
● Cost/Day: 6830 DKK ( 16,808,425.10 LBP )
● Cost/Month: 6830 DKK ( 16,808,425.10 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 6830 DKK ( 16,808,425.10 LBP )
● Cost/Day: 6830 DKK ( 16,808,425.10 LBP )
● Cost/Month: 6830 DKK ( 16,808,425.10 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 6830 DKK ( 16,808,425.10 LBP )
● Cost/Day: 6830 DKK ( 16,808,425.10 LBP )
● Cost/Month: 6830 DKK ( 16,808,425.10 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 6830 DKK ( 16,808,425.10 LBP )
● Cost/Day: 6830 DKK ( 16,808,425.10 LBP )
● Cost/Month: 6830 DKK ( 16,808,425.10 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 833,9 EUR ( 15,310,581.65 LBP )
● Cost/Day: 833,9 EUR ( 15,310,581.65 LBP )
● Cost/Month: 833,9 EUR ( 15,310,581.65 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 833,9 EUR ( 15,310,581.65 LBP )
● Cost/Day: 833,9 EUR ( 15,310,581.65 LBP )
● Cost/Month: 833,9 EUR ( 15,310,581.65 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 833,9 EUR ( 15,310,581.65 LBP )
● Cost/Day: 833,9 EUR ( 15,310,581.65 LBP )
● Cost/Month: 833,9 EUR ( 15,310,581.65 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 833,9 EUR ( 15,310,581.65 LBP )
● Cost/Day: 833,9 EUR ( 15,310,581.65 LBP )
● Cost/Month: 833,9 EUR ( 15,310,581.65 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 829,83 EUR ( 15,237,061.45 LBP )
● Cost/Day: 829,83 EUR ( 15,237,061.45 LBP )
● Cost/Month: 829,83 EUR ( 15,237,061.45 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 829,83 EUR ( 15,237,061.45 LBP )
● Cost/Day: 829,83 EUR ( 15,237,061.45 LBP )
● Cost/Month: 829,83 EUR ( 15,237,061.45 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 829,83 EUR ( 15,237,061.45 LBP )
● Cost/Day: 829,83 EUR ( 15,237,061.45 LBP )
● Cost/Month: 829,83 EUR ( 15,237,061.45 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 829,83 EUR ( 15,237,061.45 LBP )
● Cost/Day: 829,83 EUR ( 15,237,061.45 LBP )
● Cost/Month: 829,83 EUR ( 15,237,061.45 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 821,18 EUR ( 15,090,021.05 LBP )
● Cost/Day: 821,18 EUR ( 15,090,021.05 LBP )
● Cost/Month: 821,18 EUR ( 15,090,021.05 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 821,18 EUR ( 15,090,021.05 LBP )
● Cost/Day: 821,18 EUR ( 15,090,021.05 LBP )
● Cost/Month: 821,18 EUR ( 15,090,021.05 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 821,18 EUR ( 15,090,021.05 LBP )
● Cost/Day: 821,18 EUR ( 15,090,021.05 LBP )
● Cost/Month: 821,18 EUR ( 15,090,021.05 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 821,18 EUR ( 15,090,021.05 LBP )
● Cost/Day: 821,18 EUR ( 15,090,021.05 LBP )
● Cost/Month: 821,18 EUR ( 15,090,021.05 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 687,15 JOD ( 14,660,710.53 LBP )
● Cost/Day: 687,15 JOD ( 14,660,710.53 LBP )
● Cost/Month: 687,15 JOD ( 14,660,710.53 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 687,15 JOD ( 14,660,710.53 LBP )
● Cost/Day: 687,15 JOD ( 14,660,710.53 LBP )
● Cost/Month: 687,15 JOD ( 14,660,710.53 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 687,15 JOD ( 14,660,710.53 LBP )
● Cost/Day: 687,15 JOD ( 14,660,710.53 LBP )
● Cost/Month: 687,15 JOD ( 14,660,710.53 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 687,15 JOD ( 14,660,710.53 LBP )
● Cost/Day: 687,15 JOD ( 14,660,710.53 LBP )
● Cost/Month: 687,15 JOD ( 14,660,710.53 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 19394,09 CZK ( 13,396,599.44 LBP )
● Cost/Day: 19394,09 CZK ( 13,396,599.44 LBP )
● Cost/Month: 19394,09 CZK ( 13,396,599.44 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 19394,09 CZK ( 13,396,599.44 LBP )
● Cost/Day: 19394,09 CZK ( 13,396,599.44 LBP )
● Cost/Month: 19394,09 CZK ( 13,396,599.44 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 19394,09 CZK ( 13,396,599.44 LBP )
● Cost/Day: 19394,09 CZK ( 13,396,599.44 LBP )
● Cost/Month: 19394,09 CZK ( 13,396,599.44 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 19394,09 CZK ( 13,396,599.44 LBP )
● Cost/Day: 19394,09 CZK ( 13,396,599.44 LBP )
● Cost/Month: 19394,09 CZK ( 13,396,599.44 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 7726,2 NOK ( 13,368,066.02 LBP )
● Cost/Day: 7726,2 NOK ( 13,368,066.02 LBP )
● Cost/Month: 7726,2 NOK ( 13,368,066.02 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 7726,2 NOK ( 13,368,066.02 LBP )
● Cost/Day: 7726,2 NOK ( 13,368,066.02 LBP )
● Cost/Month: 7726,2 NOK ( 13,368,066.02 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 7726,2 NOK ( 13,368,066.02 LBP )
● Cost/Day: 7726,2 NOK ( 13,368,066.02 LBP )
● Cost/Month: 7726,2 NOK ( 13,368,066.02 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 7726,2 NOK ( 13,368,066.02 LBP )
● Cost/Day: 7726,2 NOK ( 13,368,066.02 LBP )
● Cost/Month: 7726,2 NOK ( 13,368,066.02 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 686 EUR ( 12,608,714.30 LBP )
● Cost/Day: 686 EUR ( 12,608,714.30 LBP )
● Cost/Month: 686 EUR ( 12,608,714.30 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 686 EUR ( 12,608,714.30 LBP )
● Cost/Day: 686 EUR ( 12,608,714.30 LBP )
● Cost/Month: 686 EUR ( 12,608,714.30 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 686 EUR ( 12,608,714.30 LBP )
● Cost/Day: 686 EUR ( 12,608,714.30 LBP )
● Cost/Month: 686 EUR ( 12,608,714.30 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 686 EUR ( 12,608,714.30 LBP )
● Cost/Day: 686 EUR ( 12,608,714.30 LBP )
● Cost/Month: 686 EUR ( 12,608,714.30 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 681,02 EUR ( 12,516,814.05 LBP )
● Cost/Day: 681,02 EUR ( 12,516,814.05 LBP )
● Cost/Month: 681,02 EUR ( 12,516,814.05 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 681,02 EUR ( 12,516,814.05 LBP )
● Cost/Day: 681,02 EUR ( 12,516,814.05 LBP )
● Cost/Month: 681,02 EUR ( 12,516,814.05 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 681,02 EUR ( 12,516,814.05 LBP )
● Cost/Day: 681,02 EUR ( 12,516,814.05 LBP )
● Cost/Month: 681,02 EUR ( 12,516,814.05 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 681,02 EUR ( 12,516,814.05 LBP )
● Cost/Day: 681,02 EUR ( 12,516,814.05 LBP )
● Cost/Month: 681,02 EUR ( 12,516,814.05 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 6489,79 SEK ( 11,680,913.79 LBP )
● Cost/Day: 6489,79 SEK ( 11,680,913.79 LBP )
● Cost/Month: 6489,79 SEK ( 11,680,913.79 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 6489,79 SEK ( 11,680,913.79 LBP )
● Cost/Day: 6489,79 SEK ( 11,680,913.79 LBP )
● Cost/Month: 6489,79 SEK ( 11,680,913.79 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 6489,79 SEK ( 11,680,913.79 LBP )
● Cost/Day: 6489,79 SEK ( 11,680,913.79 LBP )
● Cost/Month: 6489,79 SEK ( 11,680,913.79 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 6489,79 SEK ( 11,680,913.79 LBP )
● Cost/Day: 6489,79 SEK ( 11,680,913.79 LBP )
● Cost/Month: 6489,79 SEK ( 11,680,913.79 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 607,41 EUR ( 11,156,690.35 LBP )
● Cost/Day: 607,41 EUR ( 11,156,690.35 LBP )
● Cost/Month: 607,41 EUR ( 11,156,690.35 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 607,41 EUR ( 11,156,690.35 LBP )
● Cost/Day: 607,41 EUR ( 11,156,690.35 LBP )
● Cost/Month: 607,41 EUR ( 11,156,690.35 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 607,41 EUR ( 11,156,690.35 LBP )
● Cost/Day: 607,41 EUR ( 11,156,690.35 LBP )
● Cost/Month: 607,41 EUR ( 11,156,690.35 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 607,41 EUR ( 11,156,690.35 LBP )
● Cost/Day: 607,41 EUR ( 11,156,690.35 LBP )
● Cost/Month: 607,41 EUR ( 11,156,690.35 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 551 GBP ( 11,103,074.27 LBP )
● Cost/Day: 551 GBP ( 11,103,074.27 LBP )
● Cost/Month: 551 GBP ( 11,103,074.27 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 551 GBP ( 11,103,074.27 LBP )
● Cost/Day: 551 GBP ( 11,103,074.27 LBP )
● Cost/Month: 551 GBP ( 11,103,074.27 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 551 GBP ( 11,103,074.27 LBP )
● Cost/Day: 551 GBP ( 11,103,074.27 LBP )
● Cost/Month: 551 GBP ( 11,103,074.27 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 551 GBP ( 11,103,074.27 LBP )
● Cost/Day: 551 GBP ( 11,103,074.27 LBP )
● Cost/Month: 551 GBP ( 11,103,074.27 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 5600 EGP ( 5,376,560.00 LBP )
● Cost/Day: 5600 EGP ( 5,376,560.00 LBP )
● Cost/Month: 5600 EGP ( 5,376,560.00 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 5600 EGP ( 5,376,560.00 LBP )
● Cost/Day: 5600 EGP ( 5,376,560.00 LBP )
● Cost/Month: 5600 EGP ( 5,376,560.00 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 5600 EGP ( 5,376,560.00 LBP )
● Cost/Day: 5600 EGP ( 5,376,560.00 LBP )
● Cost/Month: 5600 EGP ( 5,376,560.00 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 5600 EGP ( 5,376,560.00 LBP )
● Cost/Day: 5600 EGP ( 5,376,560.00 LBP )
● Cost/Month: 5600 EGP ( 5,376,560.00 LBP )
Neovascular (wet) Age-related macular degeneration (AMD) : (Elderly)
● Cost/Unit: 2618,34 TRY ( 5,028,366.42 LBP )
● Cost/Day: 2618,34 TRY ( 5,028,366.42 LBP )
● Cost/Month: 2618,34 TRY ( 5,028,366.42 LBP )
Visual impairment due to choroidal neovascularisation (CNV) :
● Cost/Unit: 2618,34 TRY ( 5,028,366.42 LBP )
● Cost/Day: 2618,34 TRY ( 5,028,366.42 LBP )
● Cost/Month: 2618,34 TRY ( 5,028,366.42 LBP )
Visual impairment due to diabetic macular oedema (DME) :
● Cost/Unit: 2618,34 TRY ( 5,028,366.42 LBP )
● Cost/Day: 2618,34 TRY ( 5,028,366.42 LBP )
● Cost/Month: 2618,34 TRY ( 5,028,366.42 LBP )
Visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) :
● Cost/Unit: 2618,34 TRY ( 5,028,366.42 LBP )
● Cost/Day: 2618,34 TRY ( 5,028,366.42 LBP )
● Cost/Month: 2618,34 TRY ( 5,028,366.42 LBP )
Prices are provided in Dollar ($)
You have to register to view this info

You have to register to view this info

You have to register to view this info